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NEURAL STEM/PROGENITORS AND GLIOMA
STEM-LIKE CELLS HAVE DIFFERENTIAL
SENSITIVITY TO CHEMOTHERAPY
To the Editor: Gong et al.1 compared the sensitivity
of embryonic neural stem cells (NSC) and adult glioma
stem cells (GSC) to chemotherapy. Temozolomide
(TMZ)—the most common treatment of adult glio-
mas—and the rarely used cisplatin (CDDP) were stud-
ied. Erlotinib and bortezomib were also included.
The clinical relevance of the particular agents se-
lected is unclear given the lack of single agent activity
in recurrent adult gliomas with the exception of
TMZ. GSC are relatively quiescent, radiation and
chemotherapy resistant, multipotent, and able to
self-renew.2–5 GSC exists in brain tumors although
their relative abundance and relationship with nor-
mal NSC is unclear.2–5 GSC are genomically unsta-
ble and the acquisition of stemness does not imply a
relationship with normal NSC. The authors should
have described the relationship between NSC and
GCS. In addition, Gong et al. should have explained
if GSC exist as a rare subpopulation within a glioma
and if the cell of origin for different types of glioma
affects response.
The role of NSC in adults is controversial. Gong
et al.1 reported TMZ and CDDP injure NSC while
minimally affecting GSC and postulate that TMZ
may result in cognitive injury and specifically mem-
ory loss. There are no current data to support this
hypothesis in adults treated only with TMZ. GSC
have a number of mechanisms by which resistance to
therapy is manifested, including active and upregu-
lated DNA damage repair systems; upregulated anti-
apoptotic pathways; increased expression of
multidrug transporters; and residence in microvascu-
lar niches.2–5 It is unclear whether NSC have similar
therapy-resistant mechanisms.
It is also uncertain whether the NSC sensitivity to
DNA-damaging agents reflects a paucity of DNA re-
pair following genotoxic injury. The lack of correla-
tion with MGMT and mismatch repair system seems
counterintuitive as TMZ cytotoxicity is a function of
cellular MGMT activity as well as proficient mis-
match repair. The correlation of NSC drug sensitiv-
ity with low expression of the drug transporter
system (multidrug resistance gene) is also unclear be-
cause neither TMZ nor CDDP are exported by this
system.
Regarding targeted therapy, GSC showed in-
creased drug sensitivity compared to NSC. A variety
of cell signaling pathways have been characterized for
GSC (Notch, ErbB1 and 2, hedgehog, Wnt/B-
catenin, IL6/STAT3, and CXCR1/2) although less is
known regarding NSC.5 Erlotinib, an ErbB1 inhibi-
tor, preferentially affected GSC with relative sparing
of NSC presumably due to overexpression of ErbB1
on GSC. In lieu of the lack of single agent activity for
ErbB1 inhibitors in adult glioma is the relevance of
this finding that may reflect the failure of in vitro
chemosensitivity assays to predict in vivo responses
in cancer and specifically glioma. The increased sen-
sitivity of GSC to the bortezomib was postulated to
reflect a paucity of proteasomes in GSC.
Peripheral nerve injury is dose limiting. This sug-
gests that if proteasome inhibitors easily entered the
CNS—none do at present—CNS-related drug in-
jury would likely manifest. Finally, does embry-
onic NSC as used by Gong et al. reflect adult NSC
behavior with respect to function as well as treat-
ment sensitivity?
Marc C. Chamberlain, Seattle, WA
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Reply from the Authors: We proposed an in vitro
approach to evaluate chemotherapeutics as potential
treatments for glioblastomas. We also attempted to
investigate potential causes of damage to endogenous
NSCs, which are responsible for maintaining active
neurogenesis in the adult brain.1
The choice of chemotherapeutics for our initial
studies was based on drugs most commonly used in
neuro-oncology and also those used in general oncol-
ogy. This is because drugs used for non-nervous sys-
tem tumors may still have significant nervous system
effects. For example, although the platinum adduct
agents are widely used for treatment in a variety of
cancers, a current search of the clinicaltrials.gov data-
base identifies more than 100 studies using cisplatin
or carboplatin for the treatment of CNS malignan-
cies. Moreover, the proteasome inhibitors are now
integral to multiple myeloma treatment, while the
epidermal growth factor receptor tyrosine kinase
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inhibitors are widely used in the treatment of lung
cancer.
Since the established treatment for malignant
gliomas includes radiation and chemotherapy with
temozolomide, it is hard to ascribe the cognitive
damage our patients experienced to just one of these
modalities. This underscores the need to model treat-
ment toxicity in both in vivo and in vitro models.
Although the lack of correlation between MGMT
levels, the mismatch repair system, and the NSC re-
sponse to temozolomide may seem counterintuitive,
there are other, multiple genes involved in TMZ re-
sistances including several genes involved in differen-
tiation.6 These complexities aside, Abcg2—a
multidrug resistance gene which we found to have a
lower expression in NSCs than in glioma stem-like
cells (GSCs)—has been shown to be involved in cis-
platin resistance in other cancers,7 and higher Abcg2
expression was reported in TMZ-resistant GSCs.8
Although none of the chemotherapeutics we
tested, with the exception of temozolomide, has sin-
gle activity in malignant gliomas, our data suggest
that erlotinib and bortezomib have the ability to
preferentially target GSCs, even though a subpopula-
tion of GSCs displayed resistance to even high doses
of these targeted drugs. This is not a “failure of in
vitro chemosensitivity assays to predict in vivo re-
sponses,” but rather points to a need to intelligently
design a treatment cocktail for the malignant gliomas
that target cells in different stages of differentiation.
The differential toxicity of chemotherapy for dif-
ferent neural cell populations at various stages of de-
velopment still warrants investigation. Although
adult NSCs can be harvested and cultured, they are
usually generated from anterior temporal lobe resec-
tions taken from epilepsy patients who received mul-
tiple drug treatments known to affect neurogenesis.9
The NSCs we used, although neither embryonic nor
adult but preserved from newborns,10 have been es-
tablished as the most reliable source of normal NSCs.
Daniela A. Bota, Mark E. Linskey, Philip H. Schwartz,
Irvine, CA
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